Development of a UPLC-MS/MS method for quantitation of metronidazole and 2-hydroxy metronidazole in human plasma and its application to a pharmacokinetic study.
Document Type
Article
Publication Date
8-15-2018
Identifier
DOI: 10.1016/j.jchromb.2018.06.024
Abstract
An ultra-performance liquid-chromatography mass-spectrometry (UPLC-MS/MS) method for simultaneous quantitation of metronidazole and 2-hydroxymetronidazole in human plasma was developed and validated. Metronidazole and 2-hydroxymetronidazole were extracted from a small volume of human plasma (10 μL) by hydrophilic lipophilic balanced solid phase extraction on 96-well μ-elution plates. Chromatographic separation of analytes was achieved on an Acquity UPLC BEH C18 column (1.7 μm, 2.1 × 100 mm) using gradient elution with a blend of 0.1% formic acid in water and 0.1% formic acid in methanol at a flow rate of 0.25 mL/min. Mass spectrometric detection was achieved using multiple reaction monitoring (MRM) in positive-ion electrospray-ionization (ESI) mode. Ion transitions were optimized at m/z 171.85->127.9 for metronidazole and m/z 187.9->125.9 for 2-hydroxymetronidazole. The assay was linear for both analytes over the concentration range of 0.1-300 μM; intra- and inter-assay precisions and accuracies were
Journal Title
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences
Volume
1092
First Page
272
Last Page
278
MeSH Keywords
Adolescent; Adult; Chromatography, High Pressure Liquid; Drug Stability; Humans; Limit of Detection; Linear Models; Metronidazole; Middle Aged; Reproducibility of Results; Tandem Mass Spectrometry; Young Adult
Keywords
2-Hydoxymetronidazole; Human plasma; Mass spectrometry; Metronidazole; Pharmacokinetics; UPLC-MS/MS
Recommended Citation
Stancil SL, van Haandel L, Abdel-Rahman S, Pearce RE. Development of a UPLC-MS/MS method for quantitation of metronidazole and 2-hydroxy metronidazole in human plasma and its application to a pharmacokinetic study. J Chromatogr B Analyt Technol Biomed Life Sci. 2018;1092:272-278. doi:10.1016/j.jchromb.2018.06.024